From: Shared medical appointments and patient-centered experience: a mixed-methods systematic review
First author, year | Model | Health cond(s) | Sample size (n) | Biophysical measures | Reported findings (with p-values) |
---|---|---|---|---|---|
Quantitative | |||||
Junling, 2015 | CHCC | HTN | 600 group, 604 control | ● BP | SBP decreased significantly in both group (p < 0.001) and control (p = 0.001) from baseline to follow-up, although decreases in group > control. |
● BMI | |||||
DBP decreased significantly in group (p = 0.001) but did not decrease significantly in control. | |||||
● Physical activity | |||||
BMI did not change in both. | |||||
Increases in physical activity in group (p < 0.001) more remarkable than in control. | |||||
Trento, 2001 | SMA / GV | T2DM | 56 group, 56 control | ● HbA1c | HbA1c stable in group, worsened in control (p < 0.002). |
● BMI | Tendency toward lower BMI in group (p = 0.06). | ||||
● HDL | HDL cholesterol initially similar in both but later lower in group only (p < 0.05). | ||||
● Fasting TG | Trend toward lower TG in group (p = 0.053). | ||||
Trento, 2002 | SMA / GV | T2DM | 56 group, 56 control | ● Dosage of anti-hyperglycemic agents ● Body wt, BP and CV risk ● Metabolic control: - HbA1c - BMI - HDL - Retinopathy | Dosage of hypoglycemic agents decreased (p < 0.001) among group compared to control. Body wt (p < 0.001) and BMI (p < 0.001) decreased in group but not in control. Similar reductions in BP and CV risk in group vs control, but diff significant only for DBP (p < 0.001). Significant decrease in HbA1c (p < 0.001) in group. HDL increased (p < 0.001) in group but not in control. Retinopathy progressed less in group (p = 0.009). |
Trento, 2004 | SMA / GV | T2DM (NIDDM) | 56 group, 56 control | ● HbA1c ● BMI ● HDL, TG ● Cr | HbA1c remained stable in group but progressively increased among control (p < 0.001). BMI, HDL, TG and Cr improved over 5 yrs. in group, but not significantly different from control. |
Trento, 2005 | SMA / GV | T2DM | 31 group, 31 control | ● HbA1c | HbA1c decreased in both, though not significantly. |
● Lipids (TC, HDL, TG) | TC decreased in controls (p < 0.05), while HDL increased in group (p = 0.027). | ||||
● Body wt, BMI | No significant modifications in other clinical variables monitored (body wt, BMI, FBG, insulin dosage, TG, ACR, foot ulcers). | ||||
● FBG | |||||
● Insulin dosage | |||||
● ACR | |||||
● Foot ulcers | |||||
Trento, 2010 | SMA / GV | T2DM (NIDDM) | 421 group, 394 control | ● FBG ● HbA1c | FBG, HbA1c, TC, TG, LDL cholesterol, SBP, DBP, and BMI decreased in group from baseline to year 4 compared to control (p < 0.001, for all measures). HDL increased in group (p < 0.001). |
● TC, LDL, HDL, TG | Cr did not change significantly in group. BMI, HbA1c, TG, and Cr increased in control, whereas total, HDL, and LDL cholesterol and SBP did not change and DBP decreased. | ||||
● BP | |||||
● BMI | |||||
● Cr | |||||
Naik, 2011 | SMA / GV | T2DM | 45 group, 42 control | ● HbA1c ● SBP ● BMI | Significantly greater improvements in HbA1c immediately following active Intervention and persisted at 1-year follow-up (p = 0.05). SBP and BMI were only reported at baseline, but not significantly different between both. |
Qualitative | |||||
Capello, 2008 | SMA / GV | HTN | 58 group (no control) | ● BP | Significant effects on SBP and DBP (p < 0.01). |
Raballo, 2012 | SMA / GV | T1DM, T2DM | 121 group, 121 control | ● HbA1c ● Lipids (TC, HDL, TG) ● FBG ● BMI | HbA1c lower in T1DM group than in control (p = 0.001) and not significantly so in T2DM (NS). Lower HDL in T1DM control (p = 0.002), but no other significant differences among both. |
Mixed Methods | |||||
Krzywkowski-Mohn, 2008 | SMA / GV | T2DM | 33 group (no control) | Diabetic clinical indicators: | |
● HbA1c | Lower HbA1c after group intervention (p < 0.05). | ||||
● LDL | Lower LDL after 18 mos (p < 0.05). | ||||
● BP | No significant diff. in SBP or DBP after 18 mos. | ||||
● Retinal exam | Increase in diabetic eye exams. | ||||
● Foot exam | No diff in diabetic foot exams (96.9% pre + post). |